Epigenetic therapies represent a major strategy for hepatocellular carcinoma (HCC) because they target dysregulated gene expression programs without directly altering DNA sequence. In HCC, carcinogenesis is shaped by aberrant DNA methylation patterns, histone modifications, and non-coding RNA networks. These alterations can reactivate oncogenes, silence tumor suppressors, and remodel the tumor microenvironment. Importantly, epigenetic changes are often reversible, creating a rational therapeutic opportunity for drug development and combination regimens.
Core epigenetic mechanisms in HCC include (1) DNA methylation mediated by DNA methyltransferases (DNMTs), (2) histone acetylation regulated by histone acetyltransferases and removed by histone deacetylases (HDACs), and (3) histone and chromatin remodeling controlled by proteins that affect nucleosome positioning. When these systems become deranged, chromatin becomes either excessively closed, suppressing protective pathways, or excessively open, permitting transcription of proliferative and survival genes. Tumor immune evasion can also be reinforced through epigenetic silencing of antigen presentation components and immune checkpoint regulation.
Epigenetic drug classes most relevant to HCC include DNMT inhibitors, HDAC inhibitors, and agents targeting bromodomain-containing proteins (readers of acetyl-lysine marks) or other chromatin-associated regulators. DNMT inhibitors can demethylate promoter regions and restore expression of genes involved in cell-cycle arrest, apoptosis, and differentiation. HDAC inhibitors typically increase histone acetylation, promote a more transcriptionally permissive chromatin state, and can induce cell-cycle perturbations and apoptosis. Bromodomain inhibitors can disrupt the function of acetylation-dependent transcription complexes, altering expression of oncogenic drivers and impairing tumor growth.
Preclinical data provide mechanistic support for these therapies in HCC. Epigenetic modulation can sensitize tumor cells to DNA damage, reduce proliferative signaling, and alter epithelial-to-mesenchymal transition programs associated with metastasis. Additionally, epigenetic drugs may increase tumor immunogenicity by upregulating major histocompatibility complex (MHC) expression and promoting expression of interferon-stimulated genes. By shifting the immune landscape, they may convert immunologically “cold” tumors into more responsive ones.
A major clinical research theme is how to deploy epigenetic therapies in a way that improves efficacy while controlling toxicity. Monotherapy trials have sometimes shown limited response rates in solid tumors, reflecting tumor heterogeneity and compensatory pathways. Consequently, the field has increasingly focused on rational combinations:
1) Epigenetic therapy plus immune checkpoint inhibition: The goal is to enhance antigen presentation and immune activation so that checkpoint blockade can be more effective. Epigenetic agents may also modulate expression of immune checkpoint ligands and reduce suppressive myeloid cell recruitment.
2) Epigenetic therapy plus targeted therapy or chemotherapy: Epigenetic drugs can prime cancer cells for apoptosis or DNA damage, potentially lowering effective doses of cytotoxic or targeted agents. This may also help overcome resistance mechanisms that depend on transcriptional plasticity.
3) Combination with anti-angiogenic therapy: HCC is highly vascular, and tumor angiogenesis can be influenced by epigenetic regulation of pro-angiogenic mediators.
Clinical translation also depends on patient selection and biomarker development. Candidate biomarkers include baseline methylation signatures, expression of epigenetic regulators (e.g., DNMTs, HDACs), circulating tumor DNA methylation patterns, and transcriptional profiles associated with chromatin states. Biomarkers are critical because epigenetic dependencies may vary between etiologies of HCC (such as hepatitis B virus, hepatitis C virus, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease) and between tumor molecular subtypes.
Beyond direct antitumor effects, epigenetic therapies must be integrated with hepatic function considerations. HCC commonly coexists with cirrhosis, which constrains treatment tolerance and affects drug metabolism. Therefore, dosing strategies and trial designs must account for Child-Pugh class, bilirubin and transaminase levels, and performance status. Pharmacovigilance is essential because HDAC inhibitors and DNMT inhibitors can be associated with cytopenias, fatigue, gastrointestinal symptoms, and hepatic enzyme elevations.
In addition, emerging “next-generation” epigenetic tools aim to increase specificity and therapeutic window. These include next-in-class HDAC inhibitors designed to reduce off-target effects, more selective bromodomain inhibitors, and combinations that use epigenetic priming schedules to maximize immune engagement. Translational studies are also exploring sequential therapy approaches, where epigenetic modulation precedes immunotherapy to achieve a favorable antigenic and immune microenvironment state.
In summary, epigenetic therapies in HCC are moving toward clinical implementation because they target reversible, transcriptionally governing chromatin abnormalities that drive tumor initiation, progression, and treatment resistance. The most promising clinical strategies emphasize biomarker-guided selection and rational combinations—particularly with immune checkpoint inhibition—to leverage increased immunogenicity and overcome intrinsic resistance. Continued refinement of drug specificity, dosing in cirrhosis, and biomarker validation will determine the long-term role of epigenetic therapies as emerging clinical tools for HCC management.
Source: Gut_BMJ (Jul 25, 2026) via #RecentAdvancesInBasicScience.
Gut Journal: Read the #RecentAdvancesInBasicScience paper by Bueloni et al. entitled “Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications” via Epigenetic therapies are rapidly moving from laboratory research towards clinical. #breaking
— @Gut_BMJ May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
